Status:
NOT_YET_RECRUITING
Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke
Lead Sponsor:
The First Hospital of Jilin University
Conditions:
Stroke
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Ischemic stroke has a variety of treatments and currently drug therapy is one of the main treatments.A number of clinical studies have proved that alprostadil (PGE1) has pharmacological effects of sig...
Eligibility Criteria
Inclusion
- ischemic stroke diagnosed by CT or MRI
- Age: 18-75 years
- Pre-stroke mRS score is 0-1
- within 72 hours symptoms onset
- 4 ≤ NIHSS \<20
- Patient is willing to participate voluntarily and to sign a written patient informed consent
Exclusion
- intracranial tumors, encephalitis or lesions diagnosed by CT or MRI
- patients with thrombolytic therapy
- low platelet , blood system diseases or other bleeding tendency
- suspected subarachnoid hemorrhage or aortic dissection coma
- atrial fibrillation, myocardial infarction, heart valve disease, infective endocarditis, heart rate \<50 beats / min
- ALT or AST continued to rise more than 3 times the upper limit of normal creatinine clearance rate\<30ml/min
- Dementia and mental illness
- Patient who is participating in other trials or has been participated in other trials in recent 3 months
Key Trial Info
Start Date :
April 18 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
950 Patients enrolled
Trial Details
Trial ID
NCT03252626
Start Date
April 18 2024
End Date
June 30 2025
Last Update
April 1 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.